Results 21 to 30 of about 9,220 (202)

Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment

Journal of Nanobiotechnology, 2021
Background Hypoxia is inherent character of most solid malignancies, leading to the failure of chemotherapy, radiotherapy and immunotherapy. Atovaquone, an anti-malaria drug, can alleviate tumor hypoxia by inhibiting mitochondrial complex III activity ...
Simeng Wang, Xinrui Zhou, Zekun Zeng, Mengjun Sui, Lihong Chen, Chao Feng, Chen Huang, Qi Yang, Meiju Ji, Peng Hou   +9 more
doaj   +2 more sources

Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation

Blood Advances, 2019
: Atovaquone, a US Food and Drug Administration–approved antiparasitic drug previously shown to reduce interleukin-6/STAT3 signaling in myeloma cells, is well tolerated, and plasma concentrations of 40 to 80 µM have been achieved with pediatric and adult
Alexandra M. Stevens, Michael Xiang, Lisa N. Heppler, Isidora Tošić, Kevin Jiang, Jaime O. Munoz, Amos S. Gaikwad, Terzah M. Horton, Xin Long, Padmini Narayanan, Elizabeth L. Seashore, Maci C. Terrell, Raushan Rashid, Michael J. Krueger, Alicia E. Mangubat-Medina, Zachary T. Ball, Pavel Sumazin, Sarah R. Walker, Yoshimasa Hamada, Seiichi Oyadomari, Michele S. Redell, David A. Frank   +21 more
doaj   +2 more sources

Atovaquone attenuates experimental colitis by reducing neutrophil infiltration of colonic mucosa

Frontiers in Pharmacology, 2022
Ulcerative colitis (UC) is a chronic relapsing disease featuring aberrant accumulation of neutrophils in colonic mucosa and the luminal space. Although significant advances in UC therapy have been made with the development of novel biologics and small ...
Laura D. Manzanares, Joseph David, Xingsheng Ren, Lenore K. Yalom, Enzo B. Piccolo, Yalda Dehghan, Aidan J. David, Stephen B. Hanauer, Ronen Sumagin   +8 more
doaj   +2 more sources

A Case of Severe Pneumocystis Pneumonia in an HIV-Negative Patient Successfully Treated with Oral Atovaquone

Infection and Drug Resistance, 2023
Jun Hirai,1,2 Nobuaki Mori,1,2 Hideo Kato,3 Nobuhiro Asai,1,2 Mao Hagihara,4 Hiroshige Mikamo1,2 1Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Nagakute, Aichi, Japan; 2Department of Infection Control and Prevention ...
Hirai J, Mori N, Kato H, Asai N, Hagihara M, Mikamo H   +5 more
doaj   +2 more sources

The Antimalarial Compound Atovaquone Inhibits Zika and Dengue Virus Infection by Blocking E Protein-Mediated Membrane Fusion

Viruses, 2020
Flaviviruses bear class II fusion proteins as their envelope (E) proteins. Here, we describe the development of an in vitro quantitative mosquito-cell-based membrane-fusion assay for the E protein using dual split proteins (DSPs).
Mizuki Yamamoto, Takeshi Ichinohe, Aya Watanabe, Ayako Kobayashi, Rui Zhang, Jiping Song, Yasushi Kawaguchi, Zene Matsuda, Jun-ichiro Inoue   +8 more
doaj   +2 more sources

Atovaquone-proguanil and reduced digestive cancer risk: a Toxoplasma gondii connection [PDF]

Gut Microbes
Emerging evidence suggests microbial pathogens contribute to digestive cancer risk. Atovaquone – proguanil (A-P), an antimalarial with antiparasitic activity, has been associated with a reduced risk of colorectal cancer (CRC).
Ariel Israel, Sarah Israel, Abraham Weizman, Shai Ashkenazi, Shlomo Vinker, Eli Magen, Eugene Merzon   +6 more
doaj   +2 more sources

Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments

Journal of Infectious Diseases, 2023
Background Mpox virus (MPXV) is a zoonotic orthopoxvirus and caused an outbreak in 2022. Although tecovirimat and brincidofovir are approved as anti-smallpox drugs, their effects in mpox patients have not been well documented.
D. Akazawa, Hirofumi Ohashi, Takayuki Hishiki, Takeshi Morita, S. Iwanami, Kwang Su Kim, Y. D. Jeong, Eun-sil Park, M. Kataoka, Kaho Shionoya, Junki Mifune, K. Tsuchimoto, Shinjiro Ojima, A. Azam, Shogo Nakajima, Hyeongki Park, T. Yoshikawa, M. Shimojima, Kotaro Kiga, S. Iwami, Ken Maeda, Tadaki Suzuki, H. Ebihara, Yoshimasa Takahashi, Koichi Watashi   +24 more
semanticscholar   +1 more source

Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated

Cancers, 2023
Simple Summary Novel well-tolerated agents are urgently needed to improve outcomes for children with acute myeloid leukemia. Atovaquone is an anti-infective agent which can be used to prevent and treat a type of pneumonia that all children with acute ...
A. Stevens, E. Schafer, Minhua Li, Maci Terrell, Raushan Rashid, Hana Paek, M. Bernhardt, Allison Weisnicht, Wesley Smith, Noah J Keogh, M. Alozie, Hailey H Oviedo, Alan K Gonzalez, Tamilini Ilangovan, Alicia E. Mangubat-Medina, Haopei Wang, E. Jo, C. Rabik, C. Bocchini, S. Hilsenbeck, Z. T. Ball, T. Cooper, M. Redell   +22 more
semanticscholar   +1 more source

Babesia microti Variant With Multiple Resistance Mutations Detected in an Immunocompromised Patient Receiving Atovaquone Prophylaxis

Open Forum Infectious Diseases, 2023
We report Babesia microti genomic sequences with multiple mutations in the atovaquone-target region of cytochrome b, including a newly identified Y272S mutation, plus 1 mutation of undetermined significance in the azithromycin-associated ribosomal ...
N. Holbrook, E. Klontz, Gordon C Adams, S. Schnittman, N. Issa, S. Bond, J. Branda, J. Lemieux   +7 more
semanticscholar   +1 more source

Atovaquone exerts its anticancer effect by inhibiting Na+/K+-ATPase ion transport in canine cancer cells [PDF]

Veterinary World, 2023
Background and Aim: New anticancer drugs are being developed to avoid the toxicity and chemoresistance of the currently available drugs. The Food and Drug Administration-approved anti-malarial drug atovaquone is known to act as a selective oxidative ...
Yousef Alharbi
doaj   +1 more source